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BACKGROUND In high tuberculosis (TB) burden countries, there are few data on the performance of new molecular commercialised 
assays developed locally.
OBJECTIVE To evaluate the performance of a new molecular commercialised assay for TB diagnosis (Detect-TB) in three laboratories.
METHODS A total of 302 sputum samples from an equal number of patients with presumptive diagnosis of pulmonary tuberculosis 
(PTB) were submitted for routine smear microscopy, culture, and Detect-TB assay at three different sites in Brazil (the cities of 
Caxias do Sul, São Paulo and Canoas).
FINDINGS Seventy four (24.7%) TB cases were diagnosed (65 bacteriologically confirmed). When compared to smear microscopy/
culture results, the overall sensitivity and specificity of Detect-TB assay was 84.6% (CI 95%; 73.7-91.6) and 93.1% (CI 95%; 89.1-
95.8), respectively. When compared to bacteriological and clinical diagnostic criteria, the sensitivity and specificity of Detect-TB 
assay was 74.3% (CI 95%; 63.3-82.9) and 92.9% (CI 95%; 88.7-95.6), respectively. Among the three sites - Caxias do Sul, São 
Paulo and Canoas - the sensitivity and specificity were respectively 94.7% and 97.8%; 71.4% and 93.9%, 82.1% and 88.9%.
MAIN CONCLUSIONS These findings suggest that the Detect-TB assay could be applied routinely in reference laboratories across 
different regions in Brazil.
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The early and accurate diagnosis of tuberculosis (TB) 
remains a crucial step in the management and control of 
TB. The World Health Organization (WHO) estimates 
that one third of all TB cases remains undiagnosed (WHO 
2015). Despite the advance in TB diagnosis, with the in-
troduction of new molecular tests, the difficulties of an 
early detection of the cases remains a major challenge.
In 2014, the Brazilian Ministry of Health, follow-
ing WHO recommendations, implemented the molecu-
lar semi-automated test Xpert MTB/RIF (Cepheid Inc., 
Sunnyvale, California) in 94 of the priority cities to con-
trol TB, in order to substitute smear microscopy of patients 
with presumed diagnosis of pulmonary TB (MS/SVS 
2015). This assay provides detection of TB and rifampin 
resistance directly from untreated sputum in less than 2 h. 
The implementation of Xpert MTB/RIF in nine countries 
under programmatic conditions evaluated by Creswel et 
al. (2014), verified an increase of 30% to 50% in the num-
ber of confirmed TB cases, but there was no detectable 
increase in the number of reported cases. Similar results 
were found in a study performed in Brazil with 14 labora-
tories in two cities (Durovni et al. 2014). However, this test 
remains costly for developing nations despite subsidies, as 
it requires a constant power supply, and involves at least 
one annual calibration performed by a trained technician.
Other commercial tests, such as AccuProbe (Gen-
Probe, USA) (O’Donnell et al. 2012) and GenoType MT-
BDRPlus (Hain Life science, Germany) (Maschmann et 
al. 2013), are reliable, but too expensive for routine use 
in most low-resource countries. For these reasons, new 
molecular commercialised assays for TB diagnosis lo-
cally developed may be useful and more cost effective.
Our group has previously developed and evaluated an 
in-house polymerase chain reaction (PCR) using IS6110 
as a target and tested three different procedures to detect 
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Mycobacterium tuberculosis complex DNA: agarose gel 
electrophoresis, membrane hybridisation and microwell 
plate hybridisation (Rossetti et al. 1997, Sperhacke et al. 
2004, Verza et al. 2009, Maschmann et al. 2011, Miche-
lon et al. 2011). Based on the microwell plate hybridisa-
tion, the in-house procedure has evolved to a molecular 
kit, the Detect-TB assay that has emerged to cooperate 
with smear microscopy on TB diagnosis.
The current study describes the performance evalu-
ation of a commercial molecular assay, Detect-TB, de-
veloped by LabTest, Belo Horizonte, Brazil, which de-
tects the M. tuberculosis complex in respiratory clinical 
specimens. Taking into account the different disease 
incidence rates and laboratory characteristics, we have 
carried out a multicenter study in three Brazilian cities.
MATERIALS AND METHODS
Study sites - The multicenter study was carried out in 
three reference laboratories located in different cities in 
Brazil from January 2011 to December 2012. The aim was 
to evaluate the performance of commercial Detect-TB as-
say compared to reference standard methods. The follow-
ing laboratories were included: (a) Laboratório Especial 
de Microbiologia Clínica (LEMC), Universidade Federal 
de São Paulo (UNIFESP), São Paulo city, in the Southeast 
Region; (b) Laboratório de Microbiologia Clínica (LMC), 
Universidade de Caxias do Sul (UCS), Caxias do Sul city, 
in the South Region; and (c) Laboratório de Biologia Mo-
lecular (LBM), Universidade Luterana do Brasil, Canoas 
city, in the South Region. These sites were chosen for 
their different incidence rates of 54.2, 22.0 and 94.2 of TB 
per 100,000 inhabitants, respectively. LEMC-UNIFESP 
is a routine and research laboratory, and evaluates clinical 
samples from patients admitted to the University Hospi-
tal in São Paulo, LMC-UCS is a reference laboratory for 
clinical evaluations in Caxias do Sul, and LBM-ULBRA 
is a research laboratory that analyses clinical samples 
from Health Units in Canoas city.
Specimens and patients - 302 sputum samples (one 
sample per patient), on the basis of routine testing, from 
presumed pulmonary TB patients without primary TB 
treatment in the past, were collected to estimate the accu-
racy of the Detect-TB assay: 42 clinical specimens from 
São Paulo, 112 from Caxias do Sul, and 148 from Canoas. 
Mycobacterial cultures and smear microscopy were carried 
out for all clinical samples. Bias was minimised through 
blinding in which the technicians performing the molecular 
and reference tests were unaware of the other test results.
The sputum specimens were treated with Ziehl-
Neelsen staining and culture on Löwenstein-Jensen 
medium and identification of M. tuberculosis complex 
(MTBC) with biochemical tests, according to MS/SVS 
recommendations (MS/SVS 2008).
Procedure - The method, based on Michelon et al. 
(2011), was developed by our group at the Centro de Desen-
volvimento Científico e Tecnológico (CDCT), Fundação 
Estadual de Produção e Pesquisa em Saúde (FEPPS), Porto 
Alegre, Brazil, and patented at INPI (Instituto Nacional 
da Propriedade Industrial) under number PI 0900612-5. It 
began to be commercialised after registration at ANVISA 
with number 10009010259, named Detect-TB assay.
Briefly, M. tuberculosis (MTB)-complex DNA was 
amplified using biotinylated primers targeting the IS6110 
fragment. These amplified products were reverse-hybri-
dised on microwell plates (Nunc Immobilizer™ Amino 
Surface, Nunc A/S, Roskilde, Denmark) to a fixed ami-
nated probe complementary to the internal region of the 
amplified IS6110 fragment. The hybridisation signal 
was detected by colorimetry using the streptavidin-
peroxidase/TMB system and measured using a specto-
photometer with a 450/620 nm filter. The absorbance of 
the negative control was subtracted from the results and 
all samples with readings above 0.275 were considered 
positive for MTB complex DNA, as recommended by 
Detect-TB (Michelon et al. 2011).
Study design - To evaluate the assay at different rates of 
TB incidence and geographical locations, Detect-TB assays 
were sent to the three study sites cited above. All laboratory 
personnel involved in the study received a detailed proto-
col and underwent a one-week training course. To facilitate 
the reproducibility of the results, all tests were performed 
with commercialised assays from the same production lot, 
thereby ensuring that the tests used contained reagents 
from batches that had been produced previously and tested 
in accordance to the current Brazilian specific law (good 
manufacturing practices for the control of diagnostic prod-
ucts - ANVISA- decree 686, 08.27.1998).
Bacteriologically confirmed pulmonary tuberculosis 
(PTB) cases were defined when the patient matched at least 
one of two of the following criteria: (a) two smear positive 
for acid-fast bacilli; or (b) M. tuberculosis (Mtb) culture-
positive in respiratory specimens. Non-bacteriologically 
confirmed PTB cases were defined as those that had clini-
cal and radiological diagnosis and clinical improvement 
after six months of solely anti-TB treatment. Non-TB cases 
were defined as those that did not receive anti-TB treatment 
for the following two years, according to the Brazilian Na-
tional Disease Reporting System (SINAN).
Statistical analysis - Detect-TB assay performance 
was compared to reference standard methods: TB cases 
with bacteriologically confirmed criteria and those with 
composite criteria that include TB cases with and without 
bacteriologically confirmation. Sensitivity, specificity, 
accuracy and kappa tests were calculated using the Statis-
tical Package for Social Sciences (SPSS) v16.0. P-values 
lower than 0.05 were considered statistically significant.
Ethics - This study was approved by the Ethical 
Committee of Fundação Estadual de Produção e Pesqui-
sa em Saúde do Rio Grande do Sul (FEPPS-RS) under 
the number 01/2007.
RESULTS
The cut-off value of the assay (0.250) was defined 
previously by Michelon et al. (2011). The gray zone 
was defined as the values from 0.250 to 0.275. Overall, 
among 302 clinical samples, only 3 (0.99%) had results 
in the gray zone. All samples in the gray zone were re-
peated and the results remained inconclusive. For this 
reason, these samples were removed from the analysis.
A total of 299 sputum samples were evaluated, 74 
(24.7%) TB cases were diagnosed of which 65 were bacte-
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riologically confirmed (Table). When compared to bacte-
riological confirmed diagnosis, the overall sensitivity and 
specificity of Detect-TB assay was 84.6% (CI 95%; 73.7-
91.6) and 93.1% (CI 95%; 89.1-95.8), respectively. When 
compared to composite diagnosis criteria, the sensitivity 
and specificity of Detect-TB assay was 74.3% (CI 95%; 
63.3-82.9) and 92.9% (CI 95%; 88.7-95.6), respectively. 
Median turnaround time from sputum collection to the 
release of Detect-TB assay results was two days.
In Canoas city, 39 of the 148 analysed samples had 
positive results using smear microscopy or culture meth-
ods. Detect-TB assay showed a sensitivity of 82.1% (CI 
95%; 67.0-91.0), specificity of 88.9% (CI 95%; 81.8-93.7), 
and a kappa value of 0.682 (CI 95%; 0.611-0.766) (Table). 
According to composite diagnosis criteria, of the 148 
samples from Canoas, 41 had positive results. Detect-TB 
assay sensitivity, specificity kappa value were of 78.1% 
(CI 95%; 63.1-88.2), 90.5% (CI 95%; 83.2-94.9) and of 
0.654 (CI 95%; 0.573-0.734), respectively (Table).
At the Caxias do Sul site, 19 of the 112 samples had 
positive results using smear microscopy and/or culture 
methods. Detect-TB assay showed sensitivity of 94.7% 
(CI 95%; 90.0-99.3), specificity of 97.8% (CI 95%; 94.6-
100.0), and a kappa value of 0.907 (CI 95%; 0.848-0.965) 
(Table). According to composite diagnostic criteria, 20 
of the 112 samples tested were positive for TB. Detect-
TB assay showed sensitivity of 90.0% (CI 95%; 83.9-
96.0), specificity of 97.8% (CI 95%; 94.6-100.0), and a 
kappa value of 0.878 (CI 95%; 0.812-0.943) (Table).
In São Paulo city, seven of the 42 analysed samples 
had positive results using smear microscopy or culture 
methods. Detect-TB assay showed sensitivity of 71.4% 
(CI 95%; 56.1-86.6), specificity of 93.9% (CI 95%; 85.2-
102.0), and a kappa value of 0.654 (CI 95%; 0.494-0.813) 
(Table). According to composite diagnostic criteria, 13 
out of 42 samples at the São Paulo site tested positive. 
Detect-TB assay showed a sensitivity of 38.5% (CI 95%; 
22.1-54.8), specificity of 92.6% (CI 95%; 83.2-101.0), and 
a kappa value of 0.353 (CI 95%; 0.192-0.513) (Table).
DISCUSSION
A multicenter study was carried out for the per-
formance evaluation of the Detect-TB assay for the 
detection of M. tuberculosis complex DNA in clinical 
samples. For detection, amplified products with the ex-
pected size of 245 bp (IS6110) were reverse-hybridised 
to a microwell plate. This test was selected for its simple 
method and colorimetric end point, factors that facilitate 
the adoption of new nucleic acid amplification tests at 
laboratories at least in middle income countries that can 
provide laboratories with molecular techniques (Dowdy 
et al. 2003, van Cleeff et al. 2005).
At the three sites (Canoas, Caxias do Sul and São 
Paulo cities), when compared to confirmed bacterio-
logical diagnosis, the overall sensitivity of the Detect-
TB assay ranged from 82.1 to 97.8% and the specificity 
ranged from 71.4% to 94.7%. When compared to com-
posite diagnostic criteria, sensitivity ranged from 38.5% 
to 90.0% and specificity ranged from 88.7% to 97.8%. 
The results obtained at these sites are in agreement with 
the findings from other studies and with commercialised 
assays (Piersimoni & Scarparo 2003, Ling et al. 2008, 
Michelon et al. 2011, O’Donnell et al. 2012, Bhutia et 
al. 2013, Steingart et al. 2013). The rate of false-positive 
results in all sites were of 2.2% at Caxias do Sul, 6.9% at 
Sao Paulo and 8.1% at Canoas.
Detect-TB is an assay to be performed in research 
and/or clinical laboratories according to the manufac-
turer’s instructions. As any other molecular technique, 
good laboratory practices must be followed, including 
unidirectional workflow, different rooms for specimen 
separation and processing, and reagent preparation. The 
use of a negative control in all steps of the protocol, 
from DNA extraction to DNA amplification detection, 
ensures the identification of contamination event during 
the analysis. However, this handling procedure occurs at 
post sample separation. The higher rate of false positive 
results observed in Canoas city (8.1%) compared to the 
other sites could be explained due to cross-contamination 
that could have occurred during specimen processing. 
Although we followed all the guidelines for diagnostic 
methods, before the molecular analysis, at the Hospital 
Laboratory, the samples may have been manipulated in 
the same cabinet that the solid culture was performed, 
and this could have led to sputum contamination, which 
can only be detected at the molecular level. Generally, 
the results of Detect-TB assay showed better specific-
ity with composite diagnostic criteria when compared 
to laboratory criteria. In a previous study by our group, 
we demonstrated that smear microscopy plus Detect-
TB assay was the most cost-effective initial diagnostic 
test for active TB when applied in a prison population 
with a high prevalence of active PTB, indicating that 
Detect-TB assay has great potential to be implemented 
under routine diagnostic conditions (Schmid et al. 2014). 
The overall rate of false negatives was higher when the 
Detect-TB assay was to composite diagnostic criteria 
(6.3%) than with bacteriological criteria (3.3%). A high 
number of false-negative samples was found in São Pau-
lo (19.0% with clinical diagnosis and 4.7% with labora-
tory diagnosis). This observation is most likely related 
to the characteristics of the TB patients evaluated in a 
university hospital, which is a tertiary care unit that is 
not the reference for TB treatment. The patients assisted 
at this level of care are usually more paucibacillary, as 
reported by others (Michelon et al. 2011). The incorrect 
processing of the samples during homogenisation and 
decontamination could also have led to unequal aliquots 
during processing for smear microscopy, culture and 
PCR. This phenomenon may have resulted in an insuf-
ficient number of detectable bacilli that were suitable 
only for detection by smear or culture. In this case, an 
inappropriate sample dilution during the decontamina-
tion procedure or a sampling error could have reduced 
the sensitivity of the test, generating a false-negative 
result as described elsewhere (Woods 2001, Piersimoni 
& Scarparo 2003, Chakravorty et al. 2005). The Detect-
TB assay has proved sensitive to the detection of smear 
microscopy negative samples (Michelon et al. 2011). In 
this study, Detect-TB assay was able to detect four cases 
of smear microscopy positive with culture negative sam-
ples, probably due to the presence of non-viable bacte-
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ria, and notably detected 10 cases out of 16 of smear mi-
croscopy negative with culture positive samples. In this 
scenario, Detect-TB assay results were released in only 
two days, lower than the turnaround time related to the 
culture results (~30 days). Depending on the prevalence 
of active TB in the population, nucleic acid amplifica-
tion taken along with the full clinical picture could be 
useful to rull in or rull out the anti-TB treatment. The 
nucleic acid amplification test result is only one piece of 
evidence and would not alone define a clinical decision. 
One limitation of our study might rely on the assumption 
that we considered as TB cases those with two positive 
smear microscopy and culture negative. More than one 
sputum positive smear microscopy result supports the 
diagnosis of mycobacterial respiratory disease but does 
not allow differentiation of TB from non-mycobacterial 
disease. Additionally, it is uncommon to have non-myco-
bacterial diseases with two positive smear microscopy. 
In our sample it occurred in only three cases. Therefore, 
we can infer that those cases had a high probability to 
be active TB cases instead a non-mycobacterial disease.
There is a high degree of variability across studies in 
the accuracy of nucleic acid amplification tests. Assum-
ing the TB prevalence at each site and the accuracy based 
upon the final clinical criteria plus laboratory confirmed 
diagnosis of PTB observed at the three different labora-
tories (Table), high negative predictive values (94% in 
Canoas, 89% in Caxias and 95% in São Paulo) and mod-
erate positive predictive values (71% in Canoas, 89% in 
Caxias and 70% in São Paulo) were obtained for all sites. 
Those figures are also achieved even with Xpert MTB/
RIF. Assuming that Xpert MTB/RIF has a sensitivity of 
90% and specificity of 98%, having HIV negative pre-
sumed TB subjects evaluated at health services with TB 
prevalence of 1% at primary health care centers, 10% at 
emergency units and 20% at hospitals or reference am-
bulatory centers, the negative predictive values achieved 
with this test were respectively 99.8%, 98.8% and 97.5%, 
and positive predictive values 31.0%, 83.0%, 92.0%. 
Smear microscopy and culture techniques remain im-
portant diagnostic techniques to be used in addition to 
Xpert MTB/RIF, in regions with low TB prevalence, in 
order to increase the positive predictive value.
Therefore, molecular tests cannot replace culture but 
should be used in addition to conventional tests and clini-
cal data for TB diagnosis as highlighted by others (Pai et 
al. 2003, 2004, Piersimoni & Scarparo 2003, CDC 2009). 
Furthermore, the Detect-TB assay is similar to an ELISA 
as it requires common laboratory equipment to reference 
laboratories from middle income countries with a high 
burden of TB and HIV, and it has the advantage of being 
a low test cost (US$ 10,00), when compared to other cur-
rent molecular commercialised assays. In addition, the 
assay results, which are based on spectrophotometry, are 
independent of human interpretation, instead of visual 
interpretation colorimetric assays (Kox et al. 1996).
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